Promising ichthyosis drug trial halted early
NCT ID NCT04697056
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 31 times
Summary
This study tested a drug called imsidolimab (ANB019) for people with ichthyosis, a skin condition causing severe dryness and scaling. The trial was stopped early after enrolling only 5 participants. The goal was to see if the drug could reduce skin redness and scaling compared to a placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ICHTHYOSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Site 101
Chicago, Illinois, 60611, United States
-
Site 102
Columbus, Ohio, 43215, United States
-
Site 104
New Haven, Connecticut, 06519, United States
-
Site 105
Salt Lake City, Utah, 84132, United States
-
Site 106
Palo Alto, California, 94304, United States
-
Site 107
San Antonio, Texas, 78218, United States
-
Site 112
Miami, Florida, 33125, United States
Conditions
Explore the condition pages connected to this study.